The Companies Expect to Improve the Clinical Performance of Mammography and Drive the Earlier Detection of Breast Cancer
Chicago, IL (PRWEB) - ScreenPoint Medical announced today that it has signed a Memorandum of Understanding (MOU) with Volpara Health Technologies. Volpara will deliver ScreenPoint’s AI-based products to customers as part of its expanding VolparaEnterprise AI cloud ecosystem. Together, the two companies expect to improve the clinical performance of mammography and drive the earlier detection of breast cancer. The partnership will leverage Volpara’s growing footprint in the breast imaging marketplace and will provide a unique opportunity for ScreenPoint to enter the US market.
ScreenPoint recently announced that it has received 510(k) Clearance from the U.S. Food & Drug Administration (FDA) for Transpara™ detection and decision support software, designed to assist radiologists with the reading of screening mammograms. Transpara is the first AI application for detecting breast cancer in screening mammograms to gain 510(k) Clearance from the FDA, based on its unique functionality which interactively provides support for detection and diagnosis.
Compared to traditional mammography CAD products, ScreenPoint’s Decision Support product Transpara delivers much more clinically useful information to the radiologist,” said Dr. Ritse Mann, breast imaging specialist at Radboud University Medical Center, Nijmegen, NL, who uses the system clinically and evaluated its performance in several studies, “I can use Transpara as a second reader and its opinion is as good as when I would ask a colleague.”
Professor Nico Karssemeijer, CEO of ScreenPoint and well-known for his pioneering work in computer-aided detection and breast imaging said, "Being a co-founder, I worked with Volpara as advisor in the past and I am excited that ScreenPoint and Volpara will now partner to bring our AI solution Transpara for breast cancer detection to the US market. Volpara is well-established in the breast space in the US, and together the two companies can work to help breast practices improve cancer detection and streamline mammography reading."
Dr Ralph Highnam, CEO of Volpara Health Technologies said "Professor Karssemeijer’s seminal works on automated detection, and more recently machine learning and AI, is globally recognized as first class, and we're delighted to have ScreenPoint join our common cause. Adding an important product like Transpara Decision Support is a perfect step for us. It enriches our offering to breast imaging centers in the US and abroad, and expands the VolparaEnterprise ecosystem as we build a platform for delivering well-curated AI and other software applications for our customers.”
About ScreenPoint Medical BV
ScreenPoint Medical develops image analysis technology for automated reading of mammograms and digital breast tomosynthesis exams, exploiting Big Data, Deep Learning and the latest developments in Artificial Intelligence. ScreenPoint Medical was founded in 2014 by Nico Karssemeijer and Michael Brady, two experts in breast imaging, machine learning, computer vision, and computer-aided detection. The main office is in Nijmegen, The Netherlands.